Cipla attacks patent extension for Novo Nordisk weight loss drug
Intellectual Property 2024-10-30 11:01 pm By Andy Sidler | Melbourne
Please login to bookmark Close

Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au